Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Ovarian Cancer Treatment Drugs Market

Ovarian Cancer Treatment Drugs Market Share

Report ID: GMI7703
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Ovarian Cancer Treatment Drugs Market Share

The market is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, extensive R&D investments, and a focus on clinical trials characterize the competitive strategies. The market is dynamic, marked by ongoing advancements, regulatory approvals, and efforts to address unmet medical needs in ovarian cancer treatment.

Ovarian Cancer Treatment Drugs Market Companies

Prominent players operating in the ovarian cancer treatment drugs industry are as mentioned below:

F. Hoffmann-La Roche AG
GlaxoSmithKline Plc.
Immunogen Inc.
Astrazeneca
Merck KGaA
Oasmia Pharmaceutical AB
Clovis Oncology, Inc.
Novartis AG
Bristol-Myers Squibb Company
Pfizer Inc.
Eli Lilly and Company
Aravive Biologics
Allarity Therapeutics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for ovarian cancer treatment drugs reached USD 3.5 billion in 2023 and is projected to be worth USD 6.1 billion by 2032 driven by the high incidence of ovarian cancer globally.

The targeted therapy drugs segment accounted for 43.7% revenue share of the ovarian cancer treatment drugs industry in 2023 and is projected to record substantial growth through 2032 owing to the benefits identifying and combating cancer cells precisely and minimizing harm to healthy cells.

North America industry for ovarian cancer treatment drugs held a sizable revenue share in 2023 and is projected to record robust growth through 2032 attributed to the growing number of patients with ovarian cancer across the region.

Some of the top ovarian cancer treatment drugs industry players are F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Astrazeneca, Merck KGaA, Oasmia Pharmaceutical AB, Clovis Oncology, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Allarity Therapeutics, among others.